DOI: http://dx.doi.org/10.18203/2349-3933.ijam20213705

Study correlating interleukin-6 levels with demographics, symptomatology and clinical outcomes among COVID-19 patients

Abdul Hassan Wahid, Vallish Shenoy, Ravi K.

Abstract


Background: The objective of this study was to estimate the Interleukin-6 levels of COVID 19 patients and to find any associations between Interleukin-6 levels and age, gender, co-morbidities, symptoms, clinical outcomes and other biochemical parameters among COVID19 patients.

Methods: It was a cross sectional observational study conducted on 150 patients admitted to Victoria Hospital, Bangalore medical college from May 2020 to September 2020. Case record form with follow up chart was used to record the relevant demographic details, clinical data including symptoms, co-morbid conditions and various laboratory data. COVID 19 infection was diagnosed by RTPCR technique and severity of COVID-19 disease was classified according to WHO guidelines and guidelines laid by Ministry of Health and Family Welfare, India. Interleukin-6 levels were correlated with the above parameters.

Results: It was found that IL6 was elevated and found to be statistically significant with the presence of co-morbid conditions including Hypertension, with the presence of symptoms including fever, cough, breathlessness, with the severity of the disease, with the presence of intubation, with the mortality of the illness and strong association with neutrophil count, C-reactive protein, Ferritin and Neutrophil-Lymphocyte ratio.

Conclusions: IL6 can be used as a viable biomarker for knowing the severity of COVID19, to predict the outcome and prognosis of the patient and associations with various presenting symptoms, co-morbid conditions and other laboratory values.


Keywords


COVID-19, IL-6, Clinical outcome, Co-morbidity

Full Text:

PDF

References


Coronavirus. Who.int. Available at: https://www.who.int/health-topics/coronavirus. Accessed on 3 February, 2021.

Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ (Clinical Research Ed.). 2020;368:m1198.

Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clinica Chimica Acta. International Journal of Clinical Chemistry. 2020;508:254-66.

Hui DS, Azhar E, Madani TA, Ntoumi F, Kock R, Dar O et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases. 2020;91:264-6.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of Coronavirus. StatPearls. Treasure Island (FL): StatPearls Publishing. 2020.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of Clinical Investigation. 2020;130(5):2620-9.

Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Assessing the importance of interleukin-6 in COVID-19. Lancet Respir Med. 2021;9(2):e13.

Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur Respir J. 2020;56(4):2003006.

Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum severe acute respiratory syndrome Coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with Coronavirus disease 2019. Clin Infect Dis. 2020;71(8):1937-42.

Wang H, Luo S, Shen Y, Li M, Zhang Z, Dong Y, et al. Multiple enzyme release, inflammation storm and hypercoagulability are prominent indicators for disease progression in COVID-19: A multi-centered, correlation study with CT imaging score. SSRN Electron J. 2020. Available at: https://www.semanticscholar.org/paper/8420f5e77befa9cbd319459902df8abd1d287cb6. Accessed on 19 August, 2020.

Wilczynski SA, Wenceslau CF, McCarthy CG, Webb RC. A cytokine/bradykinin storm comparison: What is the relationship between hypertension and COVID-19? Am J Hypertens. 2021;34(4):304-6.

Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol. 2020;92(11):2283-5.

Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-8.